Table 2.
Characteristics of trials by treatment in the analysis of the primary outcome
| Treatment | Trials | Samples | Age [years] | Weight [kg] | BMI [mg/kg2] | Baseline HbA1c [%] |
|---|---|---|---|---|---|---|
| Dulaglutide 0.25 mg QW | 1 | 24 | 57.0 (7.0) | NA | 31.0 (4.0) | 7.8 (0.8) |
| Dulaglutide 0.5 mg QW | 1 | 25 | 55.0 (10.0) | NA | 33.0 (5.0) | 8.3 (1.3) |
| Dulaglutide 0.75 mg QW | 5 | 976 | 56.9 (9.6) | 85.1 (18.1) | 30.7 (5.4) | 8.1 (0.9) |
| Dulaglutide 1 mg QW | 1 | 10 | 55.0 (9.0) | NA | 34.0 (4.0) | 7.9 (0.6) |
| Dulaglutide 1.5 mg QW | 7 | 1385 | 56.8 (9.8) | 92.2 (18.4) | 32.7 (5.2) | 8.2 (0.9) |
| Dulaglutide 2 mg QW | 1 | 30 | 53.0 (11.0) | NA | 31.0 (5.0) | 8.4 (1.0) |
| Dulaglutide 3 mg QW | 1 | 15 | 53.0 (11.0) | NA | 31.0 (5.0) | 8.0 (1.1) |
| Exenatide 10 μg BID | 16 | 2276 | 56.3 (9.9) | 95.1 (19.0) | 33.4 (5.6) | 8.2 (1.0) |
| Exenatide 2 mg QW | 6 | 1425 | 56.2 (9.7) | 94.1 (20.7) | 33.1 (5.9) | 8.6 (1.0) |
| Exenatide 5 μg BID | 6 | 775 | 55.3 (9.6) | 93.1 (19.1) | 32.3 (5.6) | 8.4 (1.0) |
| Liraglutide 0.3 mg QW | 1 | 64 | 57.2 (10.8) | 92.3 (17.5) | 32.9 (3.9) | 8.1 (0.9) |
| Liraglutide 0.6 mg QW | 4 | 627 | 56.7 (10.4) | 80.5 (16.4) | 29.8 (4.7) | 8.4 (0.9) |
| Liraglutide 0.9 mg QW | 2 | 225 | 59.2 (10.6) | 68.0 (12.3) | 25.1 (3.5) | 8.1 (0.8) |
| Liraglutide 1.2 mg QW | 4 | 711 | 56.4 (9.5) | 83.7 (17.4) | 31.4 (5.0) | 8.4 (1.1) |
| Liraglutide 1.8 mg QW | 15 | 2808 | 56.8 (9.8) | 92.6 (19.9) | 32.6 (5.6) | 8.3 (0.9) |
| Lixisenatide 20 μg QD | 11 | 3327 | 56.9 (9.5) | 85.9 (19.4) | 31.6 (6.0) | 8.2 (0.8) |
| Loxenatide 100 μg QW | 2 | 303 | 52.3 (10.5) | 72.5 (12.8) | 26.4 (3.6) | 8.5 (0.9) |
| Loxenatide 200 μg QW | 2 | 291 | 52.6 (11.0) | 72.9 (13.4) | 26.5 (3.6) | 8.5 (0.9) |
Data are presented as number or mean (SD)
SD standard deviation, BMI body mass index, HbA1c hemoglobin A1c, QW once weekly, BID twice daily, QD once daily, NA not available